Thermo Fisher Scientific (TMO) CEO says pharma reshoring is going to be a tailwind in 2027 and 2028 for this industry; will be active in deploying advanced AI capabilities to drive additional cost

The CEO of Thermo Fisher Scientific highlighted a future tailwind from pharma reshoring in 2027 and 2028, suggesting potential growth opportunities in the life sciences sector.

Newsquawk StaffPublished On the live feed at 8 more headlines followed before this page went public
Newsquawk headlinesUTC

Safran (SAF FP) announces EUR 500mln share buyback

Kazakhstan confirms there was a temporary decline in oil shipments through the marine terminal in December via CPC due to drone attacks

Thermo Fisher Scientific (TMO) CEO says pharma reshoring is going to be a tailwind in 2027 and 2028 for this industry; will be active in deploying advanced AI capabilities to drive additional cost

US sells USD 6-week bills at a high rate of 3.585%, B/C 2.97x

European Closes: Euro Stoxx 50 +0.24% at 6,030, Dax 40 +0.02% at 25,411, FTSE 100 -0.03% at 10,137, CAC 40 -0.14% at 8,347, FTSE MIB -0.45% at 45,525, IBEX 35 +0.08% at 17,687, PSI +0.77% at 8,559, SMI -0.44% at 13,368, AEX +0.37% at 997.

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

Additionally, their focus on deploying advanced AI capabilities indicates a strategic push towards cost efficiency, which could enhance profitability in a competitive landscape. Investors might see this as a positive sign for longer-term prospects and operational robustness.

Related headlines

The whole workspace, free to try.

Try it free